The frequently elevated expression of mesothelin in cancer cells compared to normal cells and the immune response to mesothelin [32,34-37] have led to exploration of mesothelin as a therapeutic target for ovarian cancers [26,31,38,39]. The gene discussed is MSLN; the disease is ovarian cancer.